Organon & Co. (OGN) Reports Q2 2025 Results

Organon & Co. (NYSE:OGN) is one of the top oversold NYSE stocks to buy now. Organon & Co. (NYSE:OGN) reported its fiscal Q2 2025 results on August 5, with revenue for the quarter reaching $1.594 billion and diluted earnings per share of $0.56.

Why Organon & Co. (OGN) Surged On Thursday

A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy.

GAAP diluted earnings per share for the quarter included a $46 million gain, or $0.14 per share, for early extinguishment of debt.

Organon & Co. (NYSE:OGN) reported net income of $145 million for fiscal Q1 2025, while adjusted EBITDA (non-GAAP) was $522 million, representing an adjusted EBITDA margin of 32.7%.

Management reported that Organon & Co. (NYSE:OGN) repaid $345 million of long-term debt during fiscal Q1 2025, and is on track to attain a net debt to adjusted EBITDA ratio of less than 4.0x by year-end.

The company also raised its revenue guidance range for the full year 2025 to $6.275 billion to $6.375 billion, based on its current views of foreign exchange. Organon & Co. (NYSE:OGN) affirmed the guidance range for adjusted EBITDA margin (non-GAAP) at 31.0% to 32.0%.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.

While we acknowledge the potential of OGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.